Mediathek

February 02, 2012, Charité Berlin
Presentation of Prof. Dr. Burghardt Wittig
Webcast in German language



February 02, 2012, Charité Berlin
Presentation by Prof. Dr. Burghardt Wittig
Webcast in English language

February 02, 2012, Charité Berlin
Panel discussion: Immunotherapies and oligo-nucleotides in cancer therapy with
Prof. Dr. Burghardt Wittig
Webcast in German language

November 29, 2011, Börsenradio Network
How much cash is available and what is the cash burn rate in 2011? Current projects of MOLOGEN AG are in the areas colorectal cancer, hepatitis B and renal cancer. Interview with Jörg Petrass, CFO of MOLOGEN AG.

November 22, 2011, Thomson Reuters
Video recording
Company presentation (35')
Interview with Dr. Matthias Schroff,
CEO of MOLOGEN AG

August 30, 2011, Börsenradio Network
MOLOGEN AG announces after first evaluation of data from the clinical phase I/II study that results from renal cancer therapy clearly exceed expactations.
CEO Dr. Matthias Schroff in an interview with Börsenradio...

August 29, 2011, German Investor Television (Deutsches Anlegerfernsehen)

News from MOLOGEN: First evaluation data from clinical study with renal cancer medicine show positive results.
Interview with Dr. Matthias Schroff,
CEO of MOLOGEN AG

July 06, 2011, Börsenradio Network
With the colorectal cancer study MGN1703 MOLOGEN examines a universal cancer medicine which is supposed to boost the immune system without major side-effects. Why did MOLOGEN AG particularly select the Russian market?
CFO Jörg Petrass in an interview with Börsenradio...

January 14, 2011, German Investor Television (Deutsches Anlegerfernsehen)


The biotech company MOLOGEN AG with several interesting product candidates in its pipeline - Interview with Jörg Petrass, CFO of MOLOGEN AG

 

December 01, 2010, Börsenradio Network
The biopharmaceutical company MOLOGEN AG is searching for "just the right cells to combat cancer". The clinical study with the colorectal cancer medicine MGN1703, that is currently on-going in Germany and Austria, is also about to start in France at the end of 2010.
Börsenradio interview with Dr. Matthias Schroff,
CEO of MOLOGEN AG

August 31, 2010, German Investor Television (Deutsches Anlegerfernsehen)

MOLOGEN made great advances in cancer research between January and June.
TV interview with Dr. Matthias Schroff,
CEO of MOLOGEN AG

August 30, 2010, Börsenradio Network
MOLOGEN wants to fight cancer with the help of the immune system. According to an analyst, the biotech company MOLOGEN AG has already reached the most important goals for 2010.
Interview with Dr. Matthias Schroff, CEO of MOLOGEN AG

August 17, 2010, German Investor Television (Deutsches Anlegerfernsehen)

MOLOGEN: "A lot of development potential for the share"
In the first half of 2010, the Berlin-based MOLOGEN AG made important advances ...
Interview with Dr. Matthias Schroff, CEO of MOLOGEN AG

August 05, 2010, German Investor Television (Deutsches Anlegerfernsehen
)
The hottest leads from the stock exchange guru
Kurt Ochner.
includung: MOLOGEN AG

July 22, 2010, ServusTV, Austria
Talk in Hangar - 7

Generation genetic engineering - brilliant or enough?
Talkshow, including Prof. Burghardt Wittig

January 12, 2010, German Investor Television (Deutsches Anlegerfernsehen)

MOLOGEN: Interview with
Dr. Matthias Schroff, CEO
TV-link

June 25, 2009, German Investor Television (Deutsches Anlegerfernsehen
)
MOLOGEN: Interview with Dr. Matthias Schroff, CEO
Topics: entry into the Prime Standard / success with development / focus on different cancer medications / goals for the year and beyond / view on the share

 

Please contact us for coverage from previous years.

Contact:
Prof. Peter W. Hübner
Head of Corporate Communications

T. +49 (0) 30 - 84 17 88 - 38
F. +49 (0) 30 - 84 17 88 - 50
M. +49 (0) 171 900 10 77

[email protected]

Distribution list

If you would like to receive our press releases, please click here.